V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015819 | 160016219 | 1.54 | 121 | null | 2019-06-21 | 2019-06-21 | PEMBROLIZUMAB | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100581305 |
| 160015820 | 160016220 | 1.6 | 17.3 | Curative (C) | 2022-05-11 | 2022-05-15 | Olaparib | N | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100870587 |
| 160015822 | 160016221 | null | 85.7 | null | 2019-01-11 | 2019-06-08 | ETOP 13-18 BEAT-meso Trial | 02 | null | IVA | 100161542 |
| 160015825 | 160016222 | 1.81 | 14.3 | Palliative (P) | 2018-10-17 | 2018-12-08 | EW EuroEwing 2012 Arm B IE | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101615395 |
| 160015828 | 160016224 | null | 81.6 | Curative (C) | 2019-07-03 | 2019-07-03 | NB HRNBL | 02 | N | PAZOPANIB | 101299042 |
| 160015829 | 160016225 | 0 | 21 | Palliative (P) | 2015-09-09 | 2017-01-01 | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | Y | null | DOXORUBICIN + IFOSFAMIDE | 100658904 |
| 160015832 | 160016226 | 1.57 | 79.4 | null | 2019-08-09 | 2019-08-09 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | BRIGATINIB | 101427803 |
| 160015833 | 160016227 | 0 | 82.2 | null | 2019-07-14 | 2019-07-14 | EW EuroEwing 2012 Arm A VAI | 02 | null | IFOSFAMIDE | 100956787 |
| 160015842 | 160016228 | 0 | 28.25 | Neo-adjuvant (N) | 2020-02-28 | 2020-02-28 | ETOP 13-18 BEAT-meso Trial | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100140786 |
| 160015847 | 160016229 | 1.72 | 112 | null | 2016-04-14 | 2016-10-07 | Gemcitabine day 1&8 | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101745278 |
| 160015848 | 160016230 | 1.66 | null | Curative (C) | 2015-11-25 | 2017-08-25 | Trial Unspecified | 02 | null | TRIAL | 101437570 |
| 160015849 | 160016231 | 1.6 | 55.2 | Curative (C) | 2019-07-26 | 2019-08-03 | CONFIRM TRIAL | 02 | N | NB LOW/INTERMED RISK GUIDELINES CADO | 101610665 |
| 160015851 | 160016232 | 1.58 | 53 | Curative (C) | 2017-10-14 | 2018-03-16 | NB HRNBL-1 COJEC Ind COURSE B | N | N | EW EUROEWING 2012 ARM A VAI | 101470115 |
| 160015857 | 160016233 | 1.76 | 62 | null | 2018-10-27 | 2018-11-05 | STS Non-Rhabdo EpSSG 2005 IVA | 02 | null | IFOSFAMIDE | 101479949 |
| 160015859 | 160016234 | 1.71 | 73.7 | Curative (C) | 2014-08-12 | 2016-05-18 | Dinutuximab Beta | 02 | N | DICE TRIAL | 100282020 |
| 160015864 | 160016235 | 1.68 | null | Palliative (P) | 2021-03-03 | 2022-01-18 | IPO | 02 | null | TRIAL | 100802175 |
| 160015868 | 160016236 | null | null | Curative (C) | 2015-02-19 | 2016-08-03 | Dinutuximab Beta | 01 | Y | STS RHABDO RMS 2005 VIN CYCLO | 101234707 |
| 160015875 | 160016237 | 0 | 93.9 | null | 2020-11-24 | 2020-11-24 | Cyclophosphamide High Dose | 02 | null | TRANSPLANT MELPHALAN + TREOSULFAN | 100721031 |
| 160015880 | 160016238 | 1.8 | 80.9 | Palliative (P) | 2018-11-15 | 2018-12-14 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | CYCLOPHOSPHAMIDE + VINORELBINE | 100669712 |
| 160015890 | 160016239 | null | 73.4 | Neo-adjuvant (N) | 2019-01-23 | 2019-03-04 | IVA | 02 | N | NIRAPARIB | 100523382 |
| 160015893 | 160016240 | 1.83 | 79 | Palliative (P) | 2018-11-23 | 2019-09-10 | ATOMIC-MESO TRIAL | 02 | N | IRINOTECAN + TEMOZOLOMIDE | 101637409 |
| 160015898 | 160016241 | 1.69 | 65 | null | 2018-01-07 | 2018-01-20 | EW EuroEwing 2012 Arm B VC | 02 | null | GEMCITABINE | 100851443 |
| 160015916 | 160016243 | 0 | 39 | Palliative (P) | 2017-07-20 | 2017-07-30 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | NOT MATCHED | 101853045 |
| 160015932 | 160016245 | 1.56 | 70.78 | Curative (C) | 2018-02-02 | 2018-02-19 | Irinotecan + Temozolomide | 02 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 101462945 |
| 160015943 | 160016246 | 1.59 | 85.1 | Adjuvant (A) | 2020-12-12 | 2021-05-15 | Cyclophosphamide + Topotecan | 02 | N | EW EUROEWING 2012 ARM B VDC/IE | 101679938 |
| 160015945 | 160016247 | 1.77 | 55 | null | 2016-10-23 | 2016-11-24 | Irinotecan + Temozolomide | null | null | CNS LGG TEMOZOLOMIDE | 100565318 |
| 160015951 | 160016248 | 1.52 | 10.2 | Curative (C) | 2021-03-31 | 2021-04-14 | GEMCITABINE | 02 | N | EW EUROEWING 2012 ARM A VAI | 100041219 |
| 160015952 | 160016249 | 1.14 | 17.4 | Palliative (P) | 2018-05-07 | 2018-05-28 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | DOXORUBICIN + IFOSFAMIDE | 100137761 |
| 160015953 | 160016250 | 1.02 | 75 | null | 2016-05-06 | 2016-09-22 | Trial Unspecified | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100409884 |
| 160015965 | 160016251 | 1.65 | 31 | Curative (C) | 2019-09-15 | 2019-09-23 | ETOP 13-18 BEAT-meso Trial | 02 | N | LANREOTIDE | 101565750 |
| 160015969 | 160016252 | 1.58 | 25.7 | Curative (C) | 2018-05-08 | 2018-06-02 | Temozolomide + RT | 99 | Y | RUCAPARIB | 101127652 |
| 160015971 | 160016253 | 1.25 | 18 | null | 2018-05-31 | 2018-06-07 | NEMO TRIAL | 02 | null | EW EUROEWING 2012 ARM A VIDE | 101396540 |
| 160015973 | 160016254 | 1.6 | 40.4 | Palliative (P) | 2018-08-29 | 2019-08-28 | ETOP 13-18 BEAT-meso Trial | 02 | N | NIRAPARIB | 100533153 |
| 160015985 | 160016255 | 1.71 | 114.6 | Curative (C) | 2018-05-18 | 2018-06-14 | CARBOPLATIN + VINORELBINE | 02 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 101625524 |
| 160015987 | 160016256 | 0 | 77.8 | Curative (C) | 2016-12-18 | 2016-12-29 | STS Rhabdomyosarcoma RMS 2005 IVADo | 2 | N | GEMCITABINE | 100741713 |
| 160015988 | 160016257 | 0 | 62 | null | 2021-10-14 | 2022-01-15 | Gemcitabine weekly | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101831133 |
| 160015996 | 160016258 | 1.79 | 74.1 | Palliative (P) | 2019-10-31 | 2019-10-31 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | TRIAL | 100967871 |
| 160015998 | 160016259 | 1.56 | 104 | Palliative (P) | 2017-01-10 | 2017-01-21 | Etoposide + Ifosfamide (5 days) | 02 | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100933905 |
| 160016000 | 160016260 | 1.6 | 21.8 | Adjuvant (A) | 2017-01-21 | 2017-01-21 | NB HRNBL-1 ch14.18/CHO only (trial) | 01 | N | AZACITIDINE | 101644512 |
| 160016004 | 160016261 | null | 89.3 | Curative (C) | 2016-08-12 | 2016-08-17 | CREATE TRIAL | 02 | N | CONFIRM TRIAL | 100927957 |
| 160016007 | 160016262 | 1.82 | 69.5 | null | 2016-02-13 | 2016-04-18 | PROMISE-MESO TRIAL | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100885300 |
| 160016009 | 160016263 | 1.45 | 69.6 | Palliative (P) | 2020-06-27 | 2020-06-27 | ETOP 13-18 BEAT-meso Trial | 01 | N | OLARATUMAB | 100356006 |
| 160016013 | 160016264 | 0 | 90.8 | null | 2022-05-16 | 2022-05-18 | Olaparib | null | null | DOXORUBICIN + IFOSFAMIDE | 101056904 |
| 160016014 | 160016265 | 1.81 | 19 | Curative (C) | null | 2019-03-22 | Niraparib | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100521134 |
| 160016016 | 160016266 | 1.67 | 84.6 | Palliative (P) | 2018-06-25 | 2018-06-26 | Palbociclib | 01 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101728123 |
| 160016033 | 160016268 | 1.58 | 27.6 | null | 2017-09-13 | 2017-09-20 | DACARBAZINE + GEMCITABINE | 02 | null | EW EUROEWING 2012 ARM B VDC | 101320679 |
| 160016036 | 160016269 | 1.64 | 16.5 | Palliative (P) | 2022-01-01 | 2022-01-01 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100744831 |
| 160016038 | 160016270 | 1.62 | 49.7 | Palliative (P) | 2018-03-31 | 2018-04-01 | PEMBROLIZUMAB | 02 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 101849043 |
| 160016039 | 160016271 | null | 81.5 | null | null | 2016-10-11 | EW EuroEwing 2012 Arm B IE | 02 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 101522556 |
| 160016044 | 160016272 | 1.63 | 10.2 | Palliative (P) | 2018-05-29 | 2018-05-29 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | CISPLATIN + ETOPOSIDE | 101273053 |